Clover touts phase 3 omicron data as wait for COVID-19 vaccine approvals drags on

Clover Biopharmaceuticals is fighting to establish a toehold in the COVID-19 vaccine space. Having missed a string of regulatory filing targets, the Chinese biotech is pitching its first-generation adjuvanted protein vaccine as a “universal booster”—and touting antibody levels against the omicron BA.5 subvariant to make its case.